Capital Management Associates NY continued to hold its stake in Bristol-Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,250 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Capital Management Associates NY’s holdings in Bristol-Myers Squibb were worth $237,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in BMY. Welch Investments LLC grew its holdings in Bristol-Myers Squibb by 3.9% in the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 79 shares during the last quarter. Crestwood Advisors Group LLC bought a new stake in Bristol-Myers Squibb in the 1st quarter worth $116,000. Blue Chip Partners Inc. grew its holdings in Bristol-Myers Squibb by 0.8% in the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 17 shares during the last quarter. Proficio Capital Partners LLC grew its holdings in Bristol-Myers Squibb by 29.6% in the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 504 shares during the last quarter. Finally, American National Bank grew its holdings in Bristol-Myers Squibb by 11.7% in the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 225 shares during the last quarter. 68.80% of the stock is currently owned by institutional investors and hedge funds.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 6,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now directly owns 18,000 shares in the company, valued at $1,006,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The disclosure for this sale can be found here. 0.23% of the stock is owned by corporate insiders.
A number of equities research analysts have issued reports on BMY shares. Jefferies Group LLC reissued a “buy” rating and issued a $64.00 price target on shares of Bristol-Myers Squibb in a report on Monday, June 5th. Vetr raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price target on the stock in a report on Monday, June 5th. BidaskClub raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. William Blair reissued an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, June 26th. Finally, Cowen and Company set a $65.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, July 10th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $62.54.
Bristol-Myers Squibb Company (NYSE:BMY) traded down 0.35% during midday trading on Friday, reaching $62.62. 6,579,322 shares of the company traded hands. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $63.47. The company has a 50 day moving average price of $57.53 and a 200-day moving average price of $55.70. The stock has a market capitalization of $102.69 billion, a P/E ratio of 22.87 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same period in the prior year, the business earned $0.69 EPS. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. Analysts forecast that Bristol-Myers Squibb Company will post $2.98 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This report was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://sportsperspectives.com/2017/09/10/capital-management-associates-ny-has-237000-stake-in-bristol-myers-squibb-company-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.